ClinicalTrials.gg
CompletedNCT03611010Updated Jul 15, 2022Results posted

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

A Phase 2 interventional study of Atorvastatin injection in Hypercholesterolemia and Dyslipidemias, sponsored by Cumberland Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by Cumberland Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
62nd of 75
40 · median 148
Started
2018
with 3 others
Phase 2
10 of 77
none open now
Registered
72nd of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 62nd largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2018, is one of 10 in phase 2, and was the 72nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.

03

Conditions studied

  • Hypercholesterolemia
  • Dyslipidemias
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • On stable dose of daily oral atorvastatin for >= 5 weeks (oral atorvastatin may be provided during a lead-in period for subjects not previously taking atorvastatin)
  • Stable LDL-C confirmed in the previous 7 to 10 days prior to enrollment into the treatment phase.

Exclusion criteria

Exclusion Criteria:

  • History of myopathy or rhabdomyolysis
  • Liver disease including current biliary disorders
  • Positive for , or Virus
  • Abuse of alcohol or non-prescribed drugs
  • Unstable angina or arrhythmias or a cardiac event in the previous three months
  • hypothyroidism, diabetes, or hypertension that is not under control
  • pregnant or plans to be pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 = Baseline daily dose of 10 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days

    Drug: Atorvastatin injection

  • Experimental
    Cohort 2

    Cohort 2 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days

    Drug: Atorvastatin injection

  • Experimental
    Cohort 3

    Cohort 3 = Baseline daily dose of 40 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days

    Drug: Atorvastatin injection

  • Experimental
    Cohort 4

    Cohort 4 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then SC study drug for up to 15 days

    Drug: Atorvastatin injection

Interventions

  • statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection

06

What researchers measure

Primary outcomes

  1. Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C

    LDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline LDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 LDL-C not more than 125% of their baseline.

    Time frame: Baseline, 15 Days

Secondary outcomes

  1. Efficacy, Number of Participants With Day 15 HDL-C More Than or Equal to 75% Baseline HDL-C

    HDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline HDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 HDL-C not less than 75% of their baseline.

    Time frame: Baseline, 15 Days

  2. Change in Baseline LDL-C Concentration

    Mean change in LDL-C (mg/dL) from baseline at Day 15

    Time frame: Baseline, 15 days

  3. Cmax IV

    The maximum serum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.

    Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose

  4. Tmax IV

    The time to maximum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.

    Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose

  5. AUC 0-24

    The AUC 0-24 of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.

    Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose

  6. AUC Inf

    The AUCinf of atorvastatin following an intravenous injection to a patient at steady-state.

    Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose

  7. VDss

    The volume of distribution at steady state of atorvastatin following an intravenous injection to a patient.

    Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose

  8. t 1/2

    The half-life of atorvastatin following an intravenous injection to a patient at a steady state.

    Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose

07

Results

Posted Jul 15, 2022

Participant flow

Enrollment occurred between 07Aug2018 and 24Feb2020. Three types of patients, categorized by statin use prior to study participation were eligible: patients taking oral atorvastatin, patients taking statins other than atorvastatin, patient not taking any statins prior to study. In Amendment 03. the fourth 80mg dose was eliminated and the 15 days IV route administration was changed to subcutaneous administration.

Period 1: Lead-In
Participant flow — Period 1: Lead-In
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started1414210
Completed1414210
Not completed0000
Period 2: 15 Day Treatment
Participant flow — Period 2: 15 Day Treatment
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started1414210
Completed1314210
Not completed1000
Withdrew: Inaccessible veins1000

Outcome measures

PrimaryEfficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C

LDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline LDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 LDL-C not more than 125% of their baseline.

Time frame:
Baseline, 15 Days
Reported as:
Count of participants · Participants
Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C9917
SecondaryEfficacy, Number of Participants With Day 15 HDL-C More Than or Equal to 75% Baseline HDL-C

HDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline HDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 HDL-C not less than 75% of their baseline.

Time frame:
Baseline, 15 Days
Reported as:
Count of participants · Participants
Efficacy, Number of Participants With Day 15 HDL-C More Than or Equal to 75% Baseline HDL-C
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Efficacy, Number of Participants With Day 15 HDL-C More Than or Equal to 75% Baseline HDL-C111319
SecondaryChange in Baseline LDL-C Concentration

Mean change in LDL-C (mg/dL) from baseline at Day 15

Time frame:
Baseline, 15 days
Reported as:
Mean · mg/dL
Change in Baseline LDL-C Concentration
mg/dLCohort 1Cohort 2Cohort 3Cohort 4
Change in Baseline LDL-C Concentration12.36 ± 14.7402.62 ± 34.84427.50 ± 14.84911.22 ± 13.283
SecondaryCmax IV

The maximum serum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.

Time frame:
3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Reported as:
Mean · mg/mL
Cmax IV
mg/mLCohort 1Cohort 2Cohort 3
Atorvastatin284.33 ± 189.540830.34 ± 1141.919507.50 ± 443.456
2-Hydroxy Atorvastatin0.40 ± 0.871.23 ± 0.4503.23 ± 1.987
4-Hydroxy Atorvastatin0.24 ± 00.30 ± 0.1630.75 ± 0.370
SecondaryTmax IV

The time to maximum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.

Time frame:
3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Reported as:
Median · hours
Tmax IV
hoursCohort 1Cohort 2Cohort 3
Atorvastatin0.08 (0.0 to 0.5)0.08 (0.0 to 0.5)0.15 (0.1 to 0.2)
2-Hydroxy Atorvastatin6.00 (6.0 to 8.0)6.0 (2.0 to 8.0)5.00 (4.0 to 6.0)
4-Hydroxy Atorvastatin0.08 (0.0 to 0.1)6.0 (0.0 to 8.0)8.0 (8.0 to 8.0)
SecondaryAUC 0-24

The AUC 0-24 of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.

Time frame:
3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Reported as:
Mean · ng*hr/mL
AUC 0-24
ng*hr/mLCohort 1Cohort 2Cohort 3
Atorvastatin72.12 ± 31.216137.04 ± 134.608212.00 ± 89.095
2-Hydroxy Atorvastatin3.35 ± 2.60316.76 ± 6.28349.20 ± 26.698
4-Hydroxy AtorvastatinNA ± NA5.45 ± 3.69112.65 ± 5.303
SecondaryAUC Inf

The AUCinf of atorvastatin following an intravenous injection to a patient at steady-state.

Time frame:
3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Reported as:
Mean · ng*hr/mL
AUC Inf
ng*hr/mLCohort 1Cohort 2Cohort 3
AUC Inf72.19 ± 31.196167.32 ± 138.099217.00 ± 89.095
SecondaryVDss

The volume of distribution at steady state of atorvastatin following an intravenous injection to a patient.

Time frame:
3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Reported as:
Mean · liter
VDss
literCohort 1Cohort 2Cohort 3
VDss71.86 ± 81.475135.53 ± 145.579182.85 ± 140.219
Secondaryt 1/2

The half-life of atorvastatin following an intravenous injection to a patient at a steady state.

Time frame:
3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Reported as:
Mean · hours
t 1/2
hoursCohort 1Cohort 2Cohort 3
t 1/24.79 ± 4.3116.22 ± 1.8846.38 ± 0.085

Adverse events

Collected over 15 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/14 (0%)0/14 (0%)4/14 (28.6%)
Cohort 20/14 (0%)0/14 (0%)1/14 (7.1%)
Cohort 30/2 (0%)0/2 (0%)1/2 (50%)
Cohort 40/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4
ErythemaSkin and subcutaneous tissue disorders0/140/141/20/10
HeadacheNervous system disorders2/140/140/20/10
Injection site painGeneral disorders0/140/140/21/10
Viral infectionInfections and infestations0/140/140/21/10
Alanine aminotransferase increasedInvestigations0/140/140/21/10
Aspartate aminotransferase increasedInvestigations0/140/140/21/10
Vision blurredEye disorders1/140/140/20/10
HypersensitivityImmune system disorders1/140/140/20/10
Lip injuryInjury, poisoning and procedural complications0/141/140/20/10
ArthralgiaMusculoskeletal and connective tissue disorders1/140/140/20/10

Baseline characteristics

Safety Population: All subjects who received at least a partial dose of investigational medicinal product. No treated subjects were excluded from the safety population.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Total
Mean44.8 ± 9.7451.4 ± 8.2146.0 ± 18.3850.4 ± 10.4748.6 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Female651517
Male891523
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Hispanic or Latino751417
Not Hispanic or Latino791623
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American560415
White982524
More than one race00000
Unknown or Not Reported00000
Prior Atorvastatin Use or Using Oral Atorvastatin
Prior Atorvastatin Use or Using Oral Atorvastatin(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Prior Atorvastatin Use or Using Oral Atorvastatin641516
Prior Statin Other than Atorvastatin Use11002
No Prior Statin Use791522
08

Study locations

1 site
  • Frontage Clinical Services
    Secaucus, New Jersey 07094, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2020, 18 months.

Results were first posted in Jul 2022, 2 years 4 months after primary completion. A results delay was requested in Jan 2021.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 18 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2018
First posted
Aug 2, 2018
StartActual
Aug 7, 2018
Primary completionActual
Feb 17, 2020
CompletionActual
Feb 24, 2020
Results delay requested
Jan 22, 2021
Results first posted
Jul 15, 2022
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03611010
Responsible party
Sponsor
First posted
Aug 2, 2018
Start date
Aug 7, 2018
Primary completion
Feb 17, 2020
Completion
Feb 24, 2020
Results posted
Jul 15, 2022
Last update
Jul 15, 2022

Study contacts

Gregory Tracey, MD
principal investigator · Frontage Lab

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion